Radiotherapy Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Radiotherapy Market Trends and Insights

Precision-Medicine Push for Sub-Millimeter Dose Delivery

Image-guided platforms that integrate cone-beam CT and real-time tumor tracking now support daily adaptive replanning, reducing healthy-tissue margins by half and allowing safe dose escalation.^{[1]U.S. Food and Drug Administration, “510(k) Database,” fda.gov} Early clinical data from MR-linac installations have reported 92% local control rates in oligometastatic liver lesions, representing a double-digit improvement over historical CT-guided protocols. International standards are also stricter: IEC 60601-2-64 requires an isocenter accuracy of less than 2 mm for stereotactic systems, prompting upgrades across 40% of the installed base by 2027. Proton systems now ship with pencil-beam scanning at 2 mm spot sizes, helping pediatric centers spare cognitive structures during cranial treatments. Commissioning these high-precision units, however, is lengthened when physicist vacancies persist, thereby prolonging go-live timelines.

Reimbursement Expansion for Outpatient RT Procedures

In January 2025, the Centers for Medicare & Medicaid Services equalized payment for outpatient stereotactic body radiotherapy with hospital-based delivery, releasing an estimated USD 420 million in annual facility fees to freestanding centers.^{[2]Centers for Medicare & Medicaid Services, “Hospital Outpatient Prospective Payment System Final Rule 2025,” cms.gov} Private insurers quickly matched policy; Anthem added lung SBRT coverage for ambulatory surgery centers two months later, influencing 14 million covered lives.^{[3]Anthem Blue Cross, “Medical Policy – Radiation Therapy,” anthem.com} Germany followed by adding intensity-modulated radiotherapy for head-and-neck cancer to its outpatient catalog, shifting almost one-fifth of cases to day-clinic settings within half a year. These moves are not uniform, as the United Kingdom retained older tariffs that reimburse proton therapy at just 60% of cost, damping investment. Japan’s 12% boost in carbon-ion therapy payments likewise highlights reimbursement as a decisive lever for technology adoption.

AI-Driven Adaptive Planning Slashing Workflow Time

Deep-learning contouring and beam-angle optimization tools have compressed radiotherapy planning from hours to under one hour in many high-volume sites, enabling 30% more patient starts with the exact headcount. A multi-site study demonstrated that AI-generated contours for head-and-neck cases required no manual edits in 78% of instances, resulting in European regulatory clearance for fully automated adaptive workflows. Professional guidelines now demand Dice similarity coefficients above 0.85, narrowing the vendor field to algorithms supported by large multicenter datasets. Vendors are embedding reinforcement learning to shorten optimization iterations, cutting physicist review time by 40% for complex spine cases. These gains permit stretched workforces to meet rising demand without immediate hardware expansion.

FLASH & Ultra-High-Dose-Rate Proof-Of-Concept Successes

First-in-human FLASH trials delivered therapeutic doses in under one second and reported zero grade-3 toxicities at six-month follow-up, suggesting a wider therapeutic window. A 40-patient abdominal FLASH proton study is underway and is expected to inform potential breakthrough designations in 2026. Major vendors have attracted USD 180 million in funding to commercialize FLASH-ready accelerators, although technical barriers include redesigns of magnetrons and the implementation of real-time dosimetry. The International Atomic Energy Agency formed a standards group to tackle measurement gaps, underscoring the long-term horizon for broad deployment. While enthusiasm is high, randomized phase-III data needed for routine reimbursement are unlikely to be available before 2029.

Linac & Proton-Room CAPEX Squeeze Amid Higher WACC

Weighted-average cost of capital rose from 5.2% in 2023 to 7.8% in 2025, stretching proton-suite payback periods to 12 years and prompting deferrals across Europe and Latin America. One leading Spanish hospital chain canceled a Madrid installation as financing costs made debt service exceed 40% of projected revenue. A U.S. survey found that 38% of community sites are delaying linac replacements, pushing the average equipment age to 11 years and increasing downtime. Vendors now offer decade-long leases that convert capital costs to operating expenses, but uptake remains modest.

Skilled Dosimetrist/Medical-Physicist Shortages

Vacancies for board-certified medical physicists reached 23% in 2025, resulting in nine-month delays for new machine commissioning and forcing existing staff to work 54-hour weeks. The United Kingdom reported 40% of departments below minimum staffing, which limited daily slots to 85% of installed capacity. India exhibits a 50% physicist gap relative to regulatory norms, necessitating cross-site sharing that compresses quality assurance cycles. Training pipelines are flat, so several countries are fast-tracking international recruitment, although relocation costs add budget pressure.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Therapy Type: External Beam Dominance Meets Systemic Surge

External beam radiotherapy led the radiotherapy market, accounting for 82.11% of the revenue share in 2025. Its broad tumor applicability and established infrastructure keep utilization high, yet treatment compression through hypofractionation moderates revenue growth. Systemic radiotherapy is projected to post a 7.86% CAGR to 2031, buoyed by the commercial success of Lutetium-177 agents such as Pluvicto, which secured expanded Medicare coverage at USD 42,500 per treatment. External-beam platforms are answering through AI-enabled adaptive workflows that reduce planning time to 52 minutes, allowing sites to accommodate higher patient volumes without adding rooms.

Systemic agents broaden access where machine capacity is saturated, especially for metastatic disease. Lutathera sales climbed 28% in 2025 as label extensions in Japan and Australia came online. Internal brachytherapy stabilizes nearly 8% of therapy revenue, as isotope logistics and SBRT competition cap further growth. Over the forecast window, external-beam volumes stay high but see share erosion as radiopharmaceuticals secure a larger metastatic niche.

By Technology: Proton Momentum Versus IMRT Ubiquity

Intensity-modulated radiotherapy captured 31.73% of the technology revenue in 2025, reflecting its status as a standard of care for prostate and head-and-neck cancers. Proton beam therapy, while smaller, is expanding at an 8.38% CAGR, assisted by Chinese provincial funding for eight new centers in 2025. Cost declines from single-room designs, now priced near USD 25 million, are drawing community hospitals into the modality.

Volumetric-modulated arc therapy reduces session times to two minutes, enabling high-throughput centers to manage rising caseloads more efficiently. Image-guided platforms hold 28% of revenue, bolstered by American College of Radiology rules that require daily imaging for stereotactic treatments. Carbon-ion therapy remains confined to a handful of Japanese and German sites due to the high capital costs of approximately USD 80 million. Overall, software-centric upgrades dominate budgets as facilities extract more productivity from legacy hardware.

By Application: Lung Gains Ground as Breast Matures

Breast cancer remained the top application, accounting for 24.48% of the revenue in 2025; however, ultra-hypofractionation reduced the number of per-patient fractions and slowed dollar growth. Lung cancer shows a 6.87% CAGR to 2031, driven by 4-fraction SBRT protocols that achieve 90% local control in surgically ineligible patients. Prostate cancer retains the second-largest share but faces payer scrutiny around proton therapy, diverting some cases back to IMRT. Head-and-neck indications benefit from daily adaptive replanning, reporting nine-point gains in two-year local control.

CNS and brain metastases rise on the back of single-fraction stereotactic radiosurgery, which compresses two-week schedules to one day and aligns with immunotherapy treatment windows. Gastrointestinal cases, notably those involving the pancreas and rectum, are increasingly migrating to MR-guided treatment for tighter margins. Across applications, oligometastatic disease management fuels extra-cranial SBRT demand as a means to delay systemic escalation.

By End User: Ambulatory Centers Capture Outpatient Shift

Hospitals and clinics delivered 61.26% of 2025 spending, leveraging integrated oncology services for complex cases. Ambulatory surgery centers are growing at a 10.15% CAGR, as reimbursement parity and five-fraction regimens make outpatient care increasingly viable. Specialty clinics, at 18% share, act as referral hubs for advanced techniques such as MR-guided or proton therapy.

Twenty-two U.S. ASCs added linacs in 2025, targeting patients with breast and prostate conditions who prefer shorter visits and free parking. Hospitals are countering this by bundling radiotherapy into six-month episode-based payments, which rewards efficiency. Certificate-of-need relaxations in eight U.S. states further lower barriers for ASC installations.

Geography Analysis

North America held 41.52% of the radiotherapy market revenue in 2025. CMS outpatient parity led to a 22% increase in equipment orders during the first half of the year, primarily at urban freestanding sites. Canada added eight linacs under rural-access grants, while Mexico’s private sector expanded volume as insurance enrollment climbed. Utilization now reaches 68% of eligible U.S. patients, approaching the plateau of mature systems.

The Asia-Pacific region is the fastest-growing, with a 9.01% CAGR. India’s USD 1.2 billion scheme to install 150 linacs aims to halve the nine-week waiting lists. Japan, South Korea, and Australia are bolstering reimbursement and workforce pipelines to support carbon-ion and proton services.

Europe accounts for 28% of revenue but faces budget constraints. Germany upgraded outpatient tariffs, shifting 18% of head-and-neck cases to day-clinic settings. The United Kingdom’s static tariff keeps proton reimbursements at 60% of cost, restraining private investment. France invested EUR 180 million to swap cobalt units for linacs, raising average dose conformality.

The Middle East and Africa together hold 6% share, dominated by Gulf Cooperation Council procurement. Saudi Arabia plans to finance eight linacs in 2025, aiming to reach four machines per million inhabitants by 2030. South America sits at a 4.5% share, with Brazil installing 12 linacs despite macroeconomic volatility.

Regulatory Landscape

Radiotherapy systems and software are regulated primarily as medical devices, while systemic radiotherapy (therapeutic radiopharmaceuticals) follows medicines pathways, creating dual-track compliance for drug-device combinations. In the United States, the FDA Office of Combination Products determines the lead center based on the principal mode of action, and in June 2025 the FDA published draft guidance to clarify Unique Device Identifier (UDI) requirements for device constituent parts used within combination products, tightening labeling and traceability expectations for manufacturers supplying oncology care pathways.

In Europe, the EU Medical Device Regulation (MDR) raises evidence and conformity-assessment demands for device components used with medicinal products, including Article 117 requirements for notified-body assessment against General Safety and Performance Requirements (GSPRs). The EMA issued an October 2024 concept paper to strengthen clinical evaluation expectations for therapeutic radiopharmaceuticals in oncology, and the European Commission issued COM(2025) 1023 in December 2025 proposing targeted MDR/IVDR updates aimed at streamlining assessments and addressing implementation bottlenecks that have affected approval timing for high-complexity radiotherapy ecosystems.

Value Chain Analysis

The radiotherapy value chain spans (1) core equipment and subassembly suppliers (linear accelerators, magnetrons, multi-leaf collimators, imaging subsystems, and treatment-planning/adaptive software), (2) OEM manufacturing, system integration, and quality testing, (3) distribution and installation, (4) site commissioning (physics acceptance testing, beam modeling, and workflow validation), and (5) lifecycle services such as software upgrades, preventive maintenance, and parts replacement. For systemic radiotherapy workflows that interface with radiotherapy departments, upstream dependencies extend to radioisotope production (reactor or accelerator-based), radiolabeling and final dose formulation, then time-critical distribution driven by short half-lives.

Operational risk concentrates at two choke points, specialist labor (medical physicists and dosimetrists) that governs commissioning speed and ongoing QA capacity, and constrained radioisotope availability for therapeutic pathways that cannot be stockpiled. The OECD Nuclear Energy Agency has highlighted structural reliance on limited reactor infrastructure and sensitive inputs such as HALEU, while the EMA Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) issued strategic recommendations in April 2025 to mitigate radiopharmaceutical supply vulnerabilities. These constraints have pushed providers and suppliers toward tighter coordination across planning software, imaging, and delivery platforms, along with deeper partnerships linking isotope producers, radiolabeling CDMOs, and treatment sites to reduce end-to-end cycle time.

Market Opportunities and Future Outlook

Workflow automation remains a clear whitespace where software can unlock additional throughput from existing hardware fleets, particularly in settings constrained by physicist availability and deferred linac replacement cycles. Multinational evidence presented around ESTRO 2026 showed an AI-based tool generating high-quality radiotherapy plans for cervical cancer in more than 95% of cases and prostate cancer in 85% of cases, with planning time reduced to around one hour. This evidence supports adoption in high-volume centers and in regions scaling access under national cancer plans.

Clinical development is also broadening the scope of radiotherapy beyond local control into more integrated, biology-informed care pathways, which increases demand for adaptive delivery, image guidance, and data integration. In 2026, peer-reviewed results in lung cancer and breast cancer highlighted strategies combining stereotactic body radiation with immunotherapy to modulate tumor biology and outcomes, reinforcing investment interest in platforms that can deliver precise hypofractionated regimens with consistent contouring, motion management, and rapid replanning. Proton therapy access initiatives in the United States (including programs discussed by the National Association for Proton Therapy in 2026) and ongoing provider system investments in adaptive radiotherapy also create tangible routes for vendors to sell upgrades, service contracts, and software add-ons that defer new-room CAPEX while expanding clinical capabilities.